Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria BioscienceLEXX +3.69%22 Quick Ratio is 10.61 as of May. 2026, which is 48% below its 10-year median of 20.26. GuruFocus rates LEXX with a GF Score™ of 22/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, Lexaria Bioscience ranks better than 80.4% on this metric.
Lexaria Bioscience has a quick ratio of 10.61. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lexaria Bioscience's Quick Ratio or its related term are showing as below:
LEXX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.86 Med: 20.26 Max: 81.13
Current: 10.61
During the past 13 years, Lexaria Bioscience's highest Quick Ratio was 81.13. The lowest was 0.86. And the median was 20.26.
LEXX's Quick Ratio is ranked better than 80.4% of 1408
companies
in the Biotechnology industry
Industry Median: 3.59
vs LEXX: 10.61
Lexaria Bioscience (NAS:LEXX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lexaria Bioscience Quick Ratio Related Terms
Lexaria Bioscience Quick Ratio Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lexaria Bioscience's Quick Ratio for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a Quick Ratio of 10.61 as of May. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lexaria Bioscience and its competitors. This is 48% below median its historical median of 20.26. Over the past decade, Lexaria Bioscience's Quick Ratio has ranged from 0.86 to 81.13. According to the industry distribution chart, Lexaria Bioscience ranks #276 out of 1408 companies in the Biotechnology industry, placing it in the top 19.6%.
Is Lexaria Bioscience's Quick Ratio too high?
Lexaria Bioscience's current Quick Ratio of 10.61 is 48% below median its 10-year median of 20.26. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 81.13. The Biotechnology industry median Quick Ratio is 3.59. Lexaria Bioscience's value of 10.61 is 195.5% above this industry median. Based on the distribution chart, Lexaria Bioscience ranks #276 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Quick Ratio compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #276 out of 1408 companies for Quick Ratio. This places Lexaria Bioscience in the top 20% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. Lexaria Bioscience's value of 10.61 is 195.5% above this benchmark. Historically, Lexaria Bioscience's own Quick Ratio has ranged from 0.86 to 81.13 over the past decade. While the company's 10-year median is 20.26 vs. the industry median of 3.59, Lexaria Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current Quick Ratio of 10.61 is 195.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current Quick Ratio is 10.61, which is 48% below median its own 10-year median of 20.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $0.54 — trading 46% above its estimated fair value. The current Quick Ratio is 10.61, which is 48% below median its 10-year median of 20.26 and 195.5% above the Biotechnology industry median of 3.59. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Quick Ratio is 10.61 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $0.54 is trading 46% above its estimated GF Value™ of $0.37.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
Quick Ratio: 10.61 (48% below median its 10-year median of 20.26)
GF Value™: $0.37 vs. price of $0.54 (46% above fair value)
Industry Position: 195.5% above the Biotechnology median (#276 of 1408)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score
Get the complete analysis for LEXX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
